At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 506 enrolled
Drug / intervention
fenofibratedrug
Likely dose
fenofibrate 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients
In Brief
A Phase 4 clinical trial evaluating fenofibrate for Dyslipidemias and 2 related conditions. Completed, enrolled 506 participants across 1 site.
Detailed Summary
Atherogenic dyslipidemia includes patients who have coronary heart disease (CHD) or CHD risk equivalents, whose TG level is not adequately controlled after statin monotherapy. According to the published ESC/EAS consensus, fibrate is suggested to be added to this type of patient who has insufficient improvement. The purpose of the study is to evaluate the efficacy on lipid control and the safety of adding fenofibrate in patients on a background of statin treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, Cardiovascular Diseases, Hypertriglyceridemia
CountriesChina
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedNov 2011
Primary CompletionFeb 2014
Study CompletionMar 2014
TodayJul 2026
First PostedNov 1, 2011
Enrollment StartOct 1, 2011
Primary CompletionFeb 1, 2014
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.7 years ago
Interventions
fenofibratedrug
Fenofibrate Capsule 200mg qd orally